Discovery of U2AF1 neoantigens in myeloid neoplasms.

"Competing interests: MB is a Founder and Scientific Advisory Board member of HighPassBio, and a Scientific Advisory Board member of Orca Bio, and has also received compensation from Miltenyi Biotec for presentations at conferences and corporate symposia pertaining to research unrelated to the current manuscript. MB and MAB have filed a provisional patent application number 63/274,681 covering applications of T cell immunotherapy for U2AF1-mutated malignancies."

"Funding: This work was supported by the MPN Research Foundation and by the Flow Cytometry, Comparative Medicine and Biostatistics Shared Resource of the Fred Hutch/University of Washington Cancer Consortium (US Department of Health and Human Services, National Institutes of Health, National Cancer Institute P30 CA015704). MAB is an Amy Strelzer Manasevit Research Program Scholar (administered by the Be The Match Foundation). MB is the recipient of the Gerdin Family Endowed Chair for Leukemia Research, Fred Hutch."